GTBL posts Rs 13.8 crore Q2 FY27 loss after forex impact
Key highlights
- GTBL reported a Rs 13.8 crore consolidated PAT loss in Q2 FY27, with a negative 27.7% PAT margin.
- GTBL recorded Rs 15.57 crore of extraordinary unrealised foreign-currency translation losses in Q2 FY27.
- Only 13 days of MBJ revenue were consolidated after the acquisition completed on September 18, 2026.
- GTBL’s standalone Q2 FY27 revenue was Rs 48 crore, while EBITDA margin declined to 37% from 48% in Q1 FY27.
powered by IRIS

Gujarat Themis Biosyn Limited (GTBL) posted a Rs 13.8 crore consolidated loss in Q2 FY27 after a Rs 15.57 crore unrealised foreign-currency translation loss, 13 days of MBJ revenue consolidation and Rs 1.2 crore of earthquake-related MBJ expenses. Interest expense was Rs 8.4 crore during the quarter.
Know Gujarat Themis Biosyn inside out
Results, valuation, peers and who's buying, in one view.
What caused GTBL’s Rs 13.8 crore consolidated loss in Q2 FY27?
GTBL’s Q2 FY27 consolidated loss was primarily affected by a Rs 15.57 crore extraordinary unrealised foreign-currency translation loss, which management identified as a one-time impact. Consolidated profit before tax was a Rs 11.2 crore loss, while tax expense of Rs 2.7 crore resulted in a Rs 13.8 crore profit-after-tax, or PAT, loss. The PAT margin was negative 27.7% on total income from operations of Rs 49.9 crore.
The timing of the MBJ acquisition also limited the revenue included in the quarter. GTBL completed the acquisition on September 18, 2026, and consolidated only 13 days of MBJ revenue in Q2 FY27. MBJ also incurred Rs 1.2 crore of one-off earthquake-related operational expenses, reported as exceptional items, while GTBL recorded Rs 8.4 crore of interest expense and Rs 4.5 crore of depreciation.
How did GTBL’s consolidated Q2 compare with H1 FY27?
GTBL’s consolidated Q2 FY27 result included a loss even though H1 FY27 reported positive EBITDA. H1 FY27 income from operations was Rs 93.7 crore and EBITDA was Rs 19.9 crore, producing a 21.2% EBITDA margin. In Q2 FY27, income from operations was Rs 49.9 crore and EBITDA was a Rs 90 lakh loss, with a negative 1.8% margin.
H1 FY27 PAT was a Rs 2.8 crore loss despite profit before tax of Rs 4 crore. The half-year included Rs 6.8 crore of tax, Rs 8.5 crore of depreciation and Rs 10.1 crore of interest. Q2 FY27 represented Rs 8.4 crore of the half-year interest charge, and GTBL attributed higher finance costs to acquisition-related debt financing.
How did GTBL’s standalone business perform in Q2 FY27?
GTBL’s standalone revenue increased to Rs 48 crore in Q2 FY27 from Rs 44 crore in Q1 FY27 and Rs 42 crore in Q2 FY26. However, standalone EBITDA declined to Rs 18 crore from Rs 21 crore in both Q1 FY27 and Q2 FY26. EBITDA margin fell to 37% in Q2 FY27, from 48% in Q1 FY27 and 49% a year earlier.
Standalone PAT was Rs 9 crore in Q2 FY27, down from Rs 11 crore in Q1 FY27 and Rs 14 crore in Q2 FY26. Its PAT margin declined to 18%, compared with 25% in Q1 FY27 and 34% a year earlier. GTBL said net profit was affected by lower operating margins and higher finance costs attributable to acquisition-related debt financing.
Got a follow-up? Ask IRIS
Why did GTBL’s standalone margin decline despite higher revenue?
GTBL said its Q2 FY27 standalone revenue remained constrained by full utilisation of the earlier 450 kilolitre, or KL, fermentation capacity. That capacity was operating at 100% utilisation, while revenue increased by Rs 4 crore sequentially to Rs 48 crore. The higher revenue therefore preceded the expected meaningful contribution from the expanded facility.
GTBL attributed the temporary Q2 FY27 decline in EBITDA and operating margins to commissioning of its new fermentation facility. Capacity has expanded to 990 KL from 450 KL, but the company said revenue benefits from the additional capacity are expected from Q4 FY27. The commissioning effect was therefore reported in Q2 FY27 before the anticipated capacity-led revenue contribution.
What is GTBL planning after the MBJ acquisition?
GTBL plans to integrate its fermentation and active pharmaceutical ingredient, or API, capabilities with MBJ’s technology platform. The company also plans to develop new fermentation-based and synthetic products, use MBJ’s specialist capabilities and expand opportunities in contract development and manufacturing organisation, or CDMO, services. The presentation describes these priorities without assigning financial targets.
GTBL also plans to use MBJ’s global customer relationships to deepen its presence in regulated and international markets. Its stated priorities include commercial execution, capacity utilisation, operational efficiencies, cash generation and disciplined management of acquisition-related funding. Those priorities follow a Q2 FY27 in which interest expense was Rs 8.4 crore and MBJ revenue was consolidated for only 13 days after the September 18, 2026 acquisition completion.
Conclusion
GTBL’s Rs 13.8 crore Q2 FY27 consolidated loss combined a Rs 15.57 crore unrealised foreign-currency translation loss, Rs 1.2 crore of earthquake-related MBJ expenses, Rs 8.4 crore of interest and a partial period of MBJ consolidation. Separately, the standalone business produced Rs 48 crore of revenue, but EBITDA and PAT margins declined during commissioning of the fermentation expansion.
The next disclosed milestone is Q4 FY27, when GTBL expects revenue benefits from fermentation capacity of 990 KL, up from 450 KL, to materialise. Longer-period MBJ consolidation, acquisition-related funding costs and execution on capacity utilisation, operational efficiency and cash generation remain matters to watch under the company’s stated plan.


